Eric K. Singhi shared the following on X:

“Our new Clinical Lung Brief Report on 1L testing & management in mNSCLC is out! With multiple frontline treatments, it’s a complex landscape!

Enjoyed collaborating with mentee Arthi Sridhar & mentor Jack West.

Key insights below, a thread:

Demographics:
– 127 respondents
– 72% respondents in Academics, 55% in the US
– 37% respondents care for >20 patients with NSCLC per week

Testing Practices:
– 93% consistently ordered NGS for non-squamous histology, but 54% for squamous
– Barriers related to logistics (76%) and reimbursement (56%) hindered molecular testing

Treatment Decisions:
– 72% awaited molecular testing before initiating systemic therapy
– 78% felt confident in interpreting NGS results
– PD-L1 expression guided treatment; pembrolizumab monotherapy preferred for high PD-L1 expression

Clinical Trials:
– Less than 50% referred patients for clinical trials in the frontline setting
– Overall survival was ranked as the most important efficacy endpoint for clinical trials

Discussion:
– Study highlights global clinician practice patterns in 1L mNSCLC management
– Challenges: decreased trial enrollment, molecular profiling turnaround times, reimbursement barriers
– Opportunities: address confidence in interpreting biomarker results, increase trial enrollment

”

Source: Eric K. Singhi/X

Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
OncoDaily
Dr. Singhi is highly skilled in general internal medicine and hematology/oncology, with a special focus on thoracic medical oncology. Fluent in multiple languages, including Hindi and Spanish, he is dedicated to providing personalized care and improving patient outcomes. Dr. Singhi’s interests extend to patient education, patient-reported outcomes, and community outreach. He is affiliated with various hospitals in the Houston area, including Harris Health Ben Taub General and LBJ Hospitals, and The University of Texas MD Anderson Cancer Center. With over 6-10 years of experience, Dr. Eric K. Singhi is committed to delivering exceptional care to his patients and advancing the field of oncology.